2025-06-13-Jefferies-阿克索姆治疗公司（AXSM）_新型偏头痛药物的推出动态-_2025年下半年销售额应稳步增长_9页_377kb

Summary of Document: Launch Dynamics for New Migraine Pill - Sales Should Grow Steadily in H2:25

Core Content

This document provides an analysis of the launch dynamics and market potential for Symbravo, an oral triptan/NSAID migraine treatment developed by Axsome Therapeutics (AXSM). It outlines the company's strategy, market expectations, and valuation considerations for Symbravo and its other CNS/neuro products.

Key Information

• Drug Overview: Symbravo is a new oral treatment for acute migraine, launched by AXSM. It is expected to compete with existing CGRP inhibitors like Nurtec (PFE) and Ubrelvy (ABBV).
• Market Opportunity: The acute migraine market is estimated to have a $300M+ opportunity, with current expectations for Symbravo's sales being relatively low due to historical precedents.
• Pricing: Symbravo has a WAC price of $1,150 for 9 pills, which is higher than some CGRP drugs but lower than others. For example, Nurtec is priced at $1,028.99 for 8 pills, and Ubrelvy at $1,041 for 10 pills.
• Sales Forecast:
  • Q2 sales are expected to be de minimis, estimated at $46K–$69K based on a conservative script count and GTN (generic therapeutic equivalent) rate.
  • The company is deploying a leaner 100-person salesforce to target 150 headache centers, which account for 67% of all branded acute migraine scripts.
• Efficacy: Symbravo shows strong efficacy in clinical trials:
  • Pain Freedom (2 hours): 19.9%
  • Most-Bothersome Symptom (MBS) Freedom (2 hours): 36.0%
  • These results are favorable compared to other drugs like Ulrely and Nurtec, though cross-trial comparisons are noted as a limitation.
• Competition and Strategy:
  • Unlike Ulrely and Nurtec, which had less strict prior treatment criteria, Symbravo's MOMENTUM and EMERGE trials included patients with inadequate responses to prior treatments, indicating a more robust clinical profile.
  • The drug's efficacy in CGRP non-responders is highlighted, with the INTERCEPT trial showing even stronger outcomes.
• Reimbursement Considerations:
  • Symbravo may face initial challenges due to high GTN (generic therapeutic equivalent) discounting and free drug use.
  • Over time, as payor access improves and free drug distribution is restricted, GTN rates are expected to rise, potentially leading to faster sales growth compared to CGRP drugs.
• Company Diversification: AXSM has three CNS/neuro products in launch, with four potentially launched by 2026, offering a diversified and de-risked commercial story.
• Profitability Outlook: The company may achieve profitability in 2026–2027.
• Valuation:
  • The current market cap is $5.2B.
  • A price target of $200.00 is set, implying a +88% return from the current price of $106.25.
  • Valuation is DCF-based, with the potential for $4.5–$6.0B valuation if Symbravo achieves peak sales of $1.5–$2B.
• Analyst Team:
  • The report is authored by Andrew Tsai, Matthew Barcus, Ph.D., John Cox, Ph.D., and Brian Balchin, ACA.
  • All analysts certify that their views are based on personal analysis and not influenced by compensation.
• Investment Recommendations:
  • The rating is BUY, indicating a potential 15%+ total return over the next 12 months.
  • AXSM is included in Jefferies Franchise Picks, a list of top stock ideas from equity analysts.
• Risks:
  • Clinical, commercial, and regulatory risks are noted.
  • The report acknowledges potential conflicts of interest due to Jefferies' business relationships with covered companies.

Main Points

• Symbravo's Launch Strategy: AXSM is taking a pragmatic, targeted approach to launch Symbravo, focusing on specialty headache centers with a smaller salesforce to optimize profitability.
• Sales Growth Expectations: Despite initial low expectations due to high GTN and free drug use, sales could accelerate in 2026 as payor access improves.
• Efficacy Advantages: Symbravo's efficacy is comparable or better than some leading CGRP drugs, especially in CGRP non-responders.
• Valuation and Potential: The company's potential peak sales could significantly increase its valuation, making its other assets call options.
• Investment Outlook: The report recommends a BUY rating for AXSM, with a price target of $200.00, based on DCF analysis and diversified product pipeline.

Conclusion

AXSM's launch of Symbravo is expected to have a modest impact on sales in the short term due to high GTN and free drug use, but long-term growth is anticipated as payor access improves and the drug's efficacy becomes more recognized. The company's diversified CNS/neuro product portfolio and potential for profitability in 2026–2027 could drive stock price appreciation, supported by a BUY rating and a price target of $200.00.